Value-based healthcare for Inflammatory Bowel Disease: improving (cost-)effectiveness
- Conditions
- Inflammatory bowel disease, Ulcerative colitis, Crohn's disease
- Registration Number
- NL-OMON21751
- Lead Sponsor
- Franciscus Gasthuis & Vlietland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 3200
Inclusion Criteria
Treated in one of the eight hospitals
At least eighteen years of age
Have had a diagnosis of IBD for at least three months
Receive a biologic agent or tofacitinib as treatment for IBD. These are the biologics currently registered for the treatment of IBD (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab), and new treatments registered during the study period.
Exclusion Criteria
Insufficient mastery of the Dutch language to fill in the questionnaires
No access to the internet to fill in the questionnaires
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient-reported, disease control, measured using the IBD-Control questionnaire (sum of questions 1,2 and 3)
- Secondary Outcome Measures
Name Time Method